Company news
Pexa Ab Class B (NGM:PEXA.B) news
Pexa Ab Class B news releases on 6ix. Latest, May 22, 2026: PEXA.B: Q1 2026 saw strong sales growth, improved results, and key research orders, but more…
Press releases & updates
PEXA.B: Q1 2026 saw strong sales growth, improved results, and key research orders, but more funding is needed
May 22, 2026
PEXA.B: Strategic refocus on lung cancer diagnostics, narrowed losses, and improved cash position
February 19, 2026
PEXA.B: Q3 revenue up 41%, rights issue secures 9.9 MSEK for diagnostic expansion
November 7, 2025
PEXA.B: Revenue up, losses narrowed, and a guaranteed rights issue launched to fund clinical expansion
August 29, 2025
PEXA.B: No Q1 revenue as PEXA pivots to clinical focus; funding needed amid strong tech validation
May 9, 2025
PEXA.B: Net loss deepens as PEXA pivots to diagnostics, seeking capital amid scientific progress
February 20, 2025
PEXA.B: Sales and earnings fell, but strong equity and new funding support global expansion and R&D
November 8, 2024
PEXA.B: Revenue fell and losses increased, but new funding and scientific milestones support future growth
August 23, 2024